SEC Tracker
Get the app
ATOS · XBRL financial data

Atossa Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ATOS's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025†Dec 31, 2025†Mar 31, 2026Jun 30, 2026
Research and development4,4675,654*3,7483,5533,4123,403*4,1575,5025,3706,156*4,7794,897
General and administrative3,0013,365*3,2323,5522,9733,748*3,2573,5383,8815,280*5,0913,797
Total operating expenses7,4689,019*6,9807,1056,3857,151*7,4149,0409,25111,436*9,8708,694
Operating income (loss)(7,468)(9,019)*(6,980)(7,105)(6,385)(7,151)*(7,414)(9,040)(9,251)(11,436)*(9,870)(8,694)
Interest income1,2741,236*1,1381,0731,001837*720645570442*309227
Other income (expense)(35)29*(36)(17)(136)(33)*(24)(28)(11)57*(28)(24)
Income tax expense (benefit)00*0000*0000*00
Net income (loss)(6,229)(7,754)*(5,878)(6,049)(7,230)(6,347)*(6,718)(8,423)(8,692)(10,937)*(9,589)(8,491)
Earnings per share, basic‡ USD per share(0.75)(0.90)*(0.75)(0.75)(0.90)(0.75)*(0.75)(1.04)(1.04)—(1.11)(0.95)
Earnings per share, diluted‡ USD per share(0.75)(0.90)*(0.75)(0.75)(0.90)(0.75)*(0.75)(1.04)(1.04)—(1.11)(0.95)
Weighted average shares, basic‡ thousands of shares8,4288,395*8,3968,4248,4278,483*8,6548,6548,654—8,6228,909
Weighted average shares, diluted‡ thousands of shares8,4288,395*8,3968,4248,4278,483*8,6548,6548,654—8,6228,909
  • ‡ Per-share figures and share counts are adjusted for the 1-for-14.925373134328357 stock split (February 2026); filings made before it reported them unadjusted.
  • † Share count changed about 1/15 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 15x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (ATOS's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025†Dec 31, 2025†Mar 31, 2026Jun 30, 2026
Cash and cash equivalents94,03188,46083,96079,52674,76671,08465,11657,85751,84541,29931,71826,094
Prepaid and other current assets—2,1621,6139879501,1651,4391,0755801,1281,8271,793
Total current assets97,64892,21987,05581,71877,11174,45768,74462,51755,67845,61836,66831,010
Total assets101,69596,25291,08785,85879,47776,44470,74764,51558,01247,60837,94332,281
Accounts payable7188061,2301,0561,5616791,1652,0103,5364,2932,5691,976
Accrued liabilities1,2619731,6131,9071,6949191,7882,2001,9891,3072,8071,380
Total current liabilities3,4445,2365,3285,6965,7964,9675,4256,8208,2258,2557,4575,451
Total liabilities3,4445,2365,3285,6965,7964,9675,4256,8208,2258,2557,4575,451
Accumulated deficit(178,534)(186,288)(192,166)(198,215)(205,445)(211,792)(218,510)(226,933)(235,625)(246,562)(256,151)(264,642)
Total stockholders' equity98,25191,01685,75980,16273,68171,47765,32257,69549,78739,35330,48626,830
Total liabilities and equity101,69596,25291,08785,85879,47776,44470,74764,51558,01247,60837,94332,281
Common shares outstanding (cover page)‡ thousands of shares8,3958,3958,4268,4268,4298,6548,6548,6548,6545778,6119,979
  • ‡ Per-share figures and share counts are adjusted for the 1-for-14.925373134328357 stock split (February 2026); filings made before it reported them unadjusted.
  • † Share count changed about 1/15 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 15x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (ATOS's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025†Dec 31, 2025†Mar 31, 2026Jun 30, 2026
Net income (loss)(6,229)(7,754)*(5,878)(6,049)(7,230)(6,347)*(6,718)(8,423)(8,692)(10,937)*(9,589)(8,491)
Stock-based compensation926*519*417352*749*774*563796*784*503*722815*
Depreciation and amortization3*———————————
Net cash from operating activities(3,883)*(5,571)*(4,698)(4,531)*(4,750)*(7,051)*(5,959)(7,259)*(6,005)*(10,539)*(9,581)(9,644)*
Purchases of property and equipment1*0*63*10*0*90*7*7*00*
Net cash from investing activities(1)*0*(6)(3)*(10)*0*(9)0*(7)*(7)*00*
Share repurchases—0*———year only——————
Net cash from financing activities(1,475)*0*204100*0*3,369*00*0*0*04,020*
Net change in cash(5,359)*(5,571)*(4,500)(4,434)*(4,760)*(3,682)*(5,968)(7,259)*(6,012)*(10,546)*(9,581)(5,624)*
  • † Share count changed about 1/15 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 15x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Atossa Therapeutics26,094not reported(9,644)*10.0M2.7 quarters 10-QJun 30, 2026
Fennec Pharmaceuticals41,24917,87450*35.1M— 10-QJun 30, 2026
Cartesian Therapeutics147,6060(21,082)*30.3M7.0 quarters 10-QJun 30, 2026
Galectin Therapeutics13,269not reported(2,439)*100.8M5.4 quarters 10-QJun 30, 2026
Achieve Life Sciences47,958not reported(10,777)*102.9M17.4 quarters 10-QJun 30, 2026
Enanta Pharmaceuticals33,41914,359(9,972)*29.1M19.0 quarters 10-QJun 30, 2026
TuHURA Biosciences996not reported(8,634)*63.7M0.1 quarters 10-QJun 30, 2026
Vaxart50,92927,1852,778*242.8M— 10-QJun 30, 2026
Ironwood Pharmaceuticals79,127113,04158,276*165.2M— 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.